Adoptive Cellular Immunotherapy of Cancer

H.C. Stevenson

1. Adoptive Cellular Immunotherapy of Cancer: An Overview 2. Lymphokine-Activated Killer Lymphocytes: Evidence for Regulation of Induction and Function by Multiple Cytokines 3. Lymphokine-Activated Killer Lymphocytes: National Cancer Institute Clinical Trials 4. Lymphokine-Activated Killer Lymphocytes: Extramural Clinical Trials 5. Lymphokine-Activated Killer Lymphocytes: Biotherapeutics Clinical Trials 6. Lymphokine-Activated Killer Lymphocytes: LAK and Interleukin-2 in the Treatment of Malignancies of the Central Nervous System 7. Activated Killer Monocytes: Preclinical Model Systems 8. Activated Killer Monocytes: Use in Clinical Trials 9. Tumor-Infiltrating Lymphocytes: Antigen-Specific Killer T-Lymphocytes or Activated Natural Killer Lymphocytes? 10. Tumor-Derived Activated Cells: Culture Conditions and Characterization 11. Clinical/Technical Challenges in Adoptive Cellular Immunotherapy: The Role of Cytapheresis 12. Clinical/Technical Challenges in Adoptive Cellular Immunotherapy : In Vitro Culture Techniques 13. Clinical/Technical Challenges in Adoptive Cellular Immunotherapy: Role of Nurses, Technicians, and Other Support Personnel 14. Adoptive Cellular Immunotherapy of Cancer: Future Perspectives